Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Driouich, Jean-Sélim, Cochin, Maxime, Lingas, Guillaume, Moureau, Grégory, Touret, Franck, Petit, Paul-Rémi, Piorkowski, Géraldine, Barthélémy, Karine, Laprie, Caroline, Coutard, Bruno, Guedj, Jérémie, de Lamballerie, Xavier, Solas, Caroline, Nougairède, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979801/
https://www.ncbi.nlm.nih.gov/pubmed/33741945
http://dx.doi.org/10.1038/s41467-021-21992-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979801/
https://www.ncbi.nlm.nih.gov/pubmed/33741945
http://dx.doi.org/10.1038/s41467-021-21992-w

Ejemplares similares